| Name | Title | Contact Details |
|---|
Syensqo is a leading science company whose ground-breaking technologies revolutionize the way we live. Our purpose is to advance human progress while cultivating a future for our planet that is not only safer and cleaner, but also inherently more sustainable, driven by the principles of circular economy. Our disruptive, market-leading solutions address fundamental megatrends. We play a key role in the future of clean mobility and bring about breakthroughs in biotechnology, natural ingredients, and circular solutions, contributing to sustainable, high-performance products for homes, food and consumer goods, planes, cars, smart devices, and healthcare applications. Inspired by the scientific councils, which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates in 30 countries.
Yokogawa Electric Corporation is a global leader in measurement, control, and information technologies. Founded in 1915 in Tokyo, Japan, the company began as a small laboratory focused on producing instruments that were primarily imported at the time. Today, Yokogawa operates in 60 countries and employs over 17,365 people, with a significant presence in North America. The company offers a diverse range of products and services, including measurement instruments, advanced control solutions for industrial automation, and information technologies for data management and analysis. Yokogawa serves various industries such as energy, chemicals, pharmaceuticals, and food, helping clients tackle complex production and operations management challenges. Their commitment to quality, innovation, and societal contribution guides their operations and partnerships with customers.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
PetVet Dx is a therapeutic management company focusing on delivering affordable, accurate, and rapid diagnostics with cutting-edge molecular technology and pharmaceuticals for veterinarians, farmers, and pet owners.